The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Abstract
Purpose: A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors. Patients and Methods: The drug was delivered by a 10-minute weekly infusion for 3 weeks followed by a week gap, with intrapatient dose escalation. Dose escalation was accomplished by doubling until grade 2 toxicity was seen. The starting dose was 5 mg/m 2. Results: Thirty-four patients received 167 infusions. CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized to the glucuronide. CA4 area under the curve (AUC) increased from 0.169 at 5 mg/m 2 to 3.29 μmol • h/L at 114 mg/m 2. The mean CA4 AUC in eight patients at 68 mg/m 2 was 2.33 μmol • h/L compared with 5.8 μmol • h/L at 25 mg/kg (the lowest effective dose) in the mouse. The only toxicity that possibly was related to the drug dose up to 40 mg/m 2 was tumor pain. Dose-limiting toxicity was reversible ataxia at 114 mg/m 2, vasovagal syncope and motor neuropathy at 88 mg/m 2, and fatal ischemia in previously irradiated bowel at 52 mg/m 2. Other drug-related grade 2 or higher toxicities seen in more than one patient were pain, lymphopenia, fatigue, anemia, diarrhea, hypertension, hypotension, vomiting, visual disturbance, and dyspnea. One patient at 68 mg/m 2 had improvement in liver metastases of adrenocortical carcinoma. Conclusion: CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg/m 2; these are doses at which tumor blood flow reduction has been recorded.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
Pettit, G. R., Singh, S. B., Hamel, E., Lin, C. M., Alberts, D. S., & Garcia-Kendal, D. (1989) · Experientia · doi:10.1007/bf01954881 · Cited by 786
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Dowlati, A., Robertson, K., Cooney, M. M., Petros, W. P., Stratford, M. R. L., Jesberger, J. A., Rafie, N., Overmoyer, B. A., Makkar, V., Stambler, B. S., et al. (2002) · PubMed · Cited by 403
Self-citationTozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R. L., Dennis, M. F., & Chaplin, D. J. (1999) · PubMed · Cited by 323
Self-citationAnti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin, D. J., Pettit, G. R., & Hill, S. A. (1999) · PubMed · Cited by 252
Endothelial cell proliferation as a novel approach to targeting tumour therapy
Denekamp, J. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.16 · Cited by 249
Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
Anderson, H. L., Yap, J. T., Miller, M. P., Robbins, A., Jones, T., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.186 · Cited by 217
Self-citationIn vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R., & Bibby, M. C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6692174 · Cited by 213
Cited by
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1628 · Cited by 930
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Medicinal Chemistry of Combretastatin A4: Present and Future Directions
Tron, G. C., Pirali, T., Sorba, G., Pagliai, F., Busacca, S., & Genazzani, A. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512903 · Cited by 629
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Metadata
- Authors
- Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-08-01
- Volume
- 21
- Issue
- 15
- Pages
- 2815-2822
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2056944384
- Cited by
- 307
- References
- 18
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results. https://app.cochat.ai/papers/10.1200/jco.2003.05.185
- The paper
- Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M. (2003). Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.05.185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.